Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Oral Mucositis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Oral Mucositis - Pipeline Review, H2 2016', provides an overview of the Oral Mucositis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Oral Mucositis - The report reviews pipeline therapeutics for Oral Mucositis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Oral Mucositis therapeutics and enlists all their major and minor projects - The report assesses Oral Mucositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Oral Mucositis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Oral Mucositis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Oral Mucositis Overview 8 Therapeutics Development 9 Pipeline Products for Oral Mucositis - Overview 9 Pipeline Products for Oral Mucositis - Comparative Analysis 10 Oral Mucositis - Therapeutics under Development by Companies 11 Oral Mucositis - Therapeutics under Investigation by Universities/Institutes 12 Oral Mucositis - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Oral Mucositis - Products under Development by Companies 16 Oral Mucositis - Products under Investigation by Universities/Institutes 17 Oral Mucositis - Companies Involved in Therapeutics Development 18 Aldeyra Therapeutics, Inc. 18 Cellceutix Corporation 19 Colby Pharmaceutical Company 20 Daewoong Pharmaceutical Co., Ltd. 21 Galera Therapeutics, Inc. 22 Onxeo SA 23 Oragenics, Inc. 24 Otsuka Holdings Co., Ltd. 25 Soligenix, Inc. 26 Spectrum Pharmaceuticals, Inc. 27 Spherium Biomed S.L. 28 Oral Mucositis - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 AG-013 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 brilacidin tetrahydrochloride - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 clonidine hydrochloride ER - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 dusquetide - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 GC-4419 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Gene Therapy for Oral Mucositis - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Gene Therapy for Oral Mucositis - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 KIN-219 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 nepidermin - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 NS-2 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 pralatrexate - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 rebamipide - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 SP-13004 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Oral Mucositis - Dormant Projects 75 Oral Mucositis - Discontinued Products 78 Oral Mucositis - Product Development Milestones 79 Featured News & Press Releases 79 Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis 79 Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference 79 Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis 80 May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol 81 Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide 81 Jan 07, 2016: Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis 82 Dec 21, 2015: SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis 83 Dec 16, 2015: Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 83 Dec 04, 2015: Soligenix Provides Clinical Program Updates on SGX942 for December 2015 85 Nov 25, 2015: FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis 85 Oct 22, 2015: Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive for Treatment of Severe Oral Mucositis 85 Oct 19, 2015: Onxeo Validive Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015 86 Sep 09, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics Annual Meeting 87 Aug 31, 2015: Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 87 Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis 88 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 89 Disclaimer 90
List of Tables
Number of Products under Development for Oral Mucositis, H2 2016 9 Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Oral Mucositis - Pipeline by Aldeyra Therapeutics, Inc., H2 2016 18 Oral Mucositis - Pipeline by Cellceutix Corporation, H2 2016 19 Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H2 2016 20 Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 21 Oral Mucositis - Pipeline by Galera Therapeutics, Inc., H2 2016 22 Oral Mucositis - Pipeline by Onxeo SA, H2 2016 23 Oral Mucositis - Pipeline by Oragenics, Inc., H2 2016 24 Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 25 Oral Mucositis - Pipeline by Soligenix, Inc., H2 2016 26 Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 27 Oral Mucositis - Pipeline by Spherium Biomed S.L., H2 2016 28 Assessment by Monotherapy Products, H2 2016 29 Number of Products by Stage and Target, H2 2016 31 Number of Products by Stage and Mechanism of Action, H2 2016 33 Number of Products by Stage and Route of Administration, H2 2016 35 Number of Products by Stage and Molecule Type, H2 2016 37 Oral Mucositis - Dormant Projects, H2 2016 75 Oral Mucositis - Dormant Projects (Contd..1), H2 2016 76 Oral Mucositis - Dormant Projects (Contd..2), H2 2016 77 Oral Mucositis - Discontinued Products, H2 2016 78
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
